Multidrug chemotherapy with concomitant interferon (IFN)-alpha was performed in a patient with chronic hepatitis lacking the hepatitis Be antigen and malignant lymphoma (ML). Levels of trans-aminases and DNA polymerase (DNA-P) values increased after the fifth course of chemotherapy. Therapy with IFN-alpha for 9 weeks induced a remission in liver disease and complete remission of ML was obtained with subsequent chemotherapy. It was possible to prevent severe liver damage by administering IFN immediately after the elevation of DNA-P. Early introduction of IFN may be effective in the prevention of fulminant hepatic failure from hepatitis from a precore mutant after chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0304-3835(97)00535-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling Prevalence, Risk Factors, and Outcomes of Hepatitis D Among Vulnerable Communities in Romania.
Viruses
December 2024
Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Background: Hepatitis B (HBV) and Delta (HDV) virus infections pose critical public health challenges, particularly in Romania, where HDV co-infection is underdiagnosed.
Methods: This study investigates the epidemiology, risk factors, and clinical outcomes of HBV/HDV co-infection in vulnerable populations, leveraging data from the LIVE(RO2) program. Conducted between July 2021 and November 2023, the program screened 320,000 individuals across 24 counties, targeting socially disadvantaged groups such as rural residents, the Roma community, and those lacking health insurance.
TIGIT-expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.
Hepatology
January 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany.
Background Aims: Bulevirtide (BLV) is a novel and the only approved treatment option for patients with chronic hepatitis D (CHD). BLV alleviates liver inflammation already early during treatment when only minor HDV RNA changes are observed. We hypothesized that BLV-treatment may influence immune cells in CHD patients and performed a high-resolution analysis of natural killer (NK) cells before and during BLV-therapy.
View Article and Find Full Text PDFA global review of national guidelines of post-exposure prophylaxis for the prevention of HIV.
J Int AIDS Soc
January 2025
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
Introduction: The World Health Organization (WHO) recommends the use of antiretroviral drugs as post-exposure prophylaxis (PEP) for preventing HIV acquisition for occupational and non-occupational exposures. To inform the development of global WHO recommendations on PEP, we reviewed national guidelines of PEP for their recommendations.
Methods: Policies addressing PEP from 38 WHO HIV priority countries were obtained by searching governmental and non-governmental websites and consulting country and regional experts; these countries were selected based on HIV burden, new HIV acquisitions and the number of HIV-associated deaths.
Prevalence of HDV infections in Poland based on the experience of a single center in Silesia and literature research.
Clin Exp Hepatol
March 2024
Department of Infectious Diseases and Hepatology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Aim Of The Study: Hepatitis delta virus (HDV) causes the most aggressive and rapidly progressive form of viral hepatitis. However, detailed data about epidemiology and risk factors in Polish population are still lacking. Thus, the aim of this retrospective study was to determine the prevalence of HDV infection among a Silesian population of patients infected with HBV.
View Article and Find Full Text PDFLong-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
Hepatology
February 2025
Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Background And Aims: Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and de novo HCC. Algorithms have been developed to stratify risk early after cure; however, data on long-term outcomes and the prognostic utility of these risk stratification algorithms at later time points are lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!